Skip to main content

Poor Physical Function Persists in Childhood Cancer Survivors

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 20, 2023.

By Lori Solomon HealthDay Reporter

MONDAY, Nov. 20, 2023 -- Despite changes in therapy, the prevalence of poor physical function has remained steady among childhood survivors of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), according to a study published online Nov. 8 in the Journal of Cancer Survivorship.

Carmen L. Wilson, from St. Jude Children's Research Hospital in Memphis, Tennessee, and colleagues examined the prevalence of reduced function among ALL and NHL survivors by treatment era. The analysis included 6,511 survivors of childhood ALL and NHL and a cohort of their siblings (4,127), participating in the Childhood Cancer Survivor Study.

The researchers found that risks for performance limitations (15.2 versus 12.5 percent; prevalence ratio [PR], 1.5), restrictions in personal care (2.0 versus 0.6 percent; PR, 3.1), routine activities (5.5 versus 1.6 percent; PR, 3.6), and work/school attendance (8.8 versus 2.1 percent; PR, 4.5) were increased in survivors compared with siblings. Between the 1970s and 1990s, the prevalence of survivors reporting reduced function did not decrease. Regardless of treatment decade, the presence of neurological and cardiovascular conditions was associated with reduced function.

"Our findings support screening for reduced physical function so that early interventions to improve physical performance and mitigate chronic disease can be initiated," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted November 2023

Read this next

CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors

THURSDAY, April 25, 2024 -- For patients with relapsed or refractory CD7-positive leukemia or lymphoma, sequential CD7 chimeric antigen receptor (CAR) T-cell therapy followed by...

Longer Exclusive Breastfeeding May Lower Risk for Childhood Hematologic Cancers

THURSDAY, March 28, 2024 -- Exclusive breastfeeding duration of at least three months may decrease the risk for childhood hematologic cancers, according to a study published...

Survival 21 Percent a Year After ICU Discharge for Blood Cancer Patients

THURSDAY, March 21, 2024 -- For hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.